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ABSTRACT: Currently chemotherapy is a widely used and important treatment for cancer. 
However, almost all the treatments have shortcomings associated with poor-specificity and high 
toxicity, which results in severe side-effects to normal cells and tissue. This is a very important problem 
yet it currently remains unanswered. Therefore, the development of method for the more effective 
delivery of anticancer drugs to their targets and real-time monitoring of the drugs localization are very 
important. Herein, we designed a theranostic prodrug: CPT-p-Leu, which was constructed using 
fluorescent camptothecin (CPT), a self-immolative linker and leucine (Leu) residue. Upon exposure 
to LAP (leucine aminopeptidase: LAP), the amide bond in CPT-p-Leu will be cleaved, followed by an 
intramolecular 1, 6-elimination, which triggers the active anticancer drug (CPT) release and recovers 
the fluorescence of CPT. With our design, the anticancer drug, CPT, can be used as both a drug and a 
fluorescence reporter, making our system suitable to accurately and effectively track the released CPT 
distribution. Based on this strategy, CPT-p-Leu could achieve the chemoselective detection of LAP 
and monitoring of the anticancer drug release. Furthermore, it also provides a very convenient way to 
accurate determine the location of the released drug in living samples. In addition, CPT-p-Leu shows 
good cell membrane permeability and enhanced cytotoxicity toward LAP overexpressing cancer cells. 
We anticipate that our research will facilitate the development of improved theranostic systems for 
cancer therapy. 
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INTRODUCTION 
Cancer is a significant life-threatening disease to humans. Currently, the treatment of cancer is focused 
on chemotherapy, surgery and radiotherapy.1-4 Chemotherapy, which is one of the most commonly 
used treatments, is hindered by unwanted and adverse side-effects, such as nausea and vomiting, hair 
loss, organ damage, and weakening of immune system, due to indiscriminate destruction of both 
cancerous and normal cells.5-8 Therefore, the development of systems, that can be precisely activated 
at the tumor site by the unique tumor microenvironment, such as high glutathione concentations, lower 
pH values, high ROSs levels and overexpression of enzymes etc.,9-24 provide a promising strategy to 
enhance the selectivity and significantly enhance the therapeutic efficiency of drugs towards cancer 
cells. 
Theranostic prodrugs, diagnostic systems combined with therapeautics have emerged as important 
treatments for diseases.25-34 In particular, theranostic prodrugs decorated with fluorophores hold the 
promise to monitor drug release by fluorescence.35-40 These kinds of theranostic prodrugs provide 
significant benefit enabling the behavior of prodrugs to be monitored. 
To date, various theranostic prodrug systems have been designed and synthesized.41-43 However, 
they are primarily focused on monitoring drug release. In such systems, the fluorophore can report 
whether the drug is released, but, it is difficult if not impossible to say exactly where the drug is located. 
Therefore, it is important to monitor both the process of drug release as well as the released drug 
cellular distribution. Because, therapeutic efficiency is closely associated with the concentration of 
antitumor drugs in cancerous tissues. 
Leucine aminopeptidase (LAP), a key proteolytic enzyme, exists widely in mammals, plants, 
microbes and cancer cells, catalyzes the hydrolysis of N-terminal leucine residues from protein or 
peptide substrates, and plays a crucial role in various pathological and physiological processes.42 A 
number of reports have indicated that LAP levels can are enhanced in various kinds of tumors, 
including ovarian epithelial malignancy and breast carcinomas, etc.45-47 Until now, LAP has been used 
as an important trigger to activate fluorescence changes in various chemosensors.48-54 As far as we are 
aware, no LAP triggered theranostic prodrug systems have previously been reported. 
Recently, Wu et al. reported a DT-diaphorase-activatable theranostic prodrug for the specific 
recognition of DT-diaphorase and monitoring drug release.19 Inspired by this strategy, herein, we 
present a LAP-activated theranostic prodrug, CPT-p-Leu, which contains an anti-cancer drug, 
camptothecin (CPT, topoisomerase I inhibitor), a cleavable and self-immolative linker, and leucine 
(Scheme 1a). In this theranostic prodrug, CPT, has two roles: First, it serves as a fluorogenic reporter 
for monitoring LAP because its fluorescence is significantly quenched by the carbonate bond. However, 
upon LAP enzymatic cleavage of the amide bond, fluorescent CPT is released after an intramolecular 
1, 6-self-elimination.55 Secondly, CPT an anticancer drug can kill cancer cells. Therefore, in our design 
the fluorescent CPT, drug can be used to accurately visualize the anticancer drugs cellular distribution, 
and provide location information to help improve therapeutic efficiency (Scheme 1b). As far as we are 
aware, CPT-p-Leu represents the first LAP-activated theranostic prodrug that can monitor LAP activity, 
report the release of the anticancer drug, and visualize the drug distribution. Resulting in a system that 




 Scheme 1. (a) CPT-p-Leu and the proposed mechanism of LAP triggering the fluorescence change and 
drug release. (b) Schematic illustration of drug release and action in cancer cells. 
 
EXPERIMENTAL SECTION 
Chemicals and Instruments: Unless specifically stated, chemical reagents and solvents were used as 
received from commercial sources. 1-Hydroxybenzotriazole (HOBt), 4-dimethylaminopyridine 
(DMAP), 2-Propanamine (DIPEA), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride 
(EDC·HCl), Tetrabutylammonium fluoride (TBAF), triphosgene, camptothecin (CPT), 
Bismuthtrichlorie (BiCl3), Boc-Leu-OH, chloride salts of metal ions (K+, Ca2+, Zn2+) were purchaused 
from Aladdin Reagents, Propidium iodide (Pi) was purchased from Tansoole. Leucine aminopeptidase 
(LAP), glutamyl transpeptidase (GGT), glutathione (GSH), cysteine (Cys), elastase (ELA), α-
chymotrypsin (α-Chy), tyrosinase (Tyr), glucoamylase, cellulase, lipase, α-amylase, aprotinin, and 
sulfatase were purchased from Sigma-Aldrich. Dichloromethane (DCM) and N, N-
dimethylformamide (DMF) both dried with calcium hydride (CaH2) and then distilled under nitrogen 
(N2). Ultrapure water was used in all tests. Column chromatography (silica gel (200-300 mesh)) was 
used for purification. 1H-NMR and 13C-NMR spectra in DMSO-d6 or CDCl3 were measured on a 
Bruker AV-400 NMR spectrometer. High resolution mass spectra (HRMS) were performed on an 
Agilent 1100 Series. UV-vis absorption and fluorescence spectra were recorded on a SHIMADZU 
UV1800 and Agilent Cary Eclipse Fluorescence spectrophotometer. High performance liquid 
chromatography (HPLC) were measured on the Dionex Ultimate 3000. The pH was determined using 
a METTLER TOLEDO FiveEasy Plus digital pH meter. 
General Optical Measurements: For in vitro measurements, CPT-p-Leu was first dissolved in 
dimethyl sulfoxide (DMSO) to prepare a parent stock solution (5.0 mM). Then an appropriate volume 
of stock solution was diluted to the desired concentration in a quartz cuvette (path length 1 cm) with 
PBS buffer for optical measurements. The relevant parameters for the measurements of fluorescence 
are as follow: the excitation wavelength was 350 nm, and slit widths: 5 nm/5 nm. 
Cell Cultures and Viability Assay: HeLa cells, A549 cells and HEK 293 cells were grown in a cell 
culture flask at 37 °C under a humidified 5% CO2/95% air incubator in Dulbecco’s modified Eagle’s 
medium (DMEM) which were supplemented with 10% fetal bovine serum (FBS) and 
penicillin−streptomycin (0.5 U·mL−1 of penicillin and 0.5·g mL−1 streptomycin). The cells (A549 cells 
and HEK293 cells) viability with CPT-p-Leu or CPT were evaluated using an MTT assay.19 For each 
independent experiment, the assays were repeated five times. 
Fluorescent confocal image of cells: Cells were seeded in a glass bottom dish with complete culture 
medium for 24 h before the experiments. Then cells were loaded with CPT-p-Leu or Pi (Propidium 
iodide) for different times in the culture medium at 37 °C. After treatment, fluorescence imaging was 
carried out using an Olympus FV1000-MP. The excitation wavelength were 405 nm and 561 nm, 
images were collected at 425-470 nm and 590 nm-650 nm for blue channel and red channel, 
respectively. 
 
RESULTS AND DISCUSSION 
CPT-p-Leu was synthesized as depicted in Scheme S1. The intermediates and the prodrug were 
confirmed by 1H NMR and 13C NMR, and high-resolution mass spectrometry (HRMS) (Figure S1-12). 
First, the optical properties of CPT-p-Leu and CPT were recorded. They both exhibited two 
absorption bands at 350 nm and 365 nm. With excitation at 350 nm, both of them possess an emission 
band at 432 nm, while the fluorescence of CPT-p-Leu is much weaker (Figure S13 and Table S1). 
These results reveal that the fluorescence of CPT is significantly reduced by the covalently attached 
group, and the fluorescence can be restored by cleavage of that group.  
Sensing Properties and Proposed Mechanism of LAP toward CPT-p-Leu. To confirm that LAP 
can cleave the amide bond in CPT-p-Leu and activate CPT fluorescence via an intramolecular 1, 6-
self-elimination. The optical properties of CPT-p-Leu in the presence of LAP under physiological 
conditions (PBS buffer solution, 10 mM, pH 7.4, 37 °C) was monitored. As depicted in Figure 1a, 
CPT-p-Leu exhibited weak fluorescence centered at 432 nm, while after treatment with LAP (0.07 
U·mL-1), the fluorescence intensity increased gradually more than 5-fold and reached a plateau after 
30 min (Figure 1c). At this point the fluorescence spectra was identical to the emission spectrum of the 
reference CPT (Figure S13b). Moreover, in order to confirm that LAP triggered the anticancer drug 
(CPT) release from CPT-p-Leu, HPLC and HRMS analysis were conducted. As shown in Figure S14, 
the retention time of pure CPT-p-Leu was found to be at 4.61 min. However, after treatment with LAP 
(0.07 U·mL-1) for 5 minutes, a new product exhibiting a chromatographic peak at 5.95 min was 
detected, which was very close to the retention time of pure CPT. Whilst, HRMS analysis of the 
reaction system indicated that, Leu, CPT and CPT-p-Leu could be observed at m/z 132.10187, 
349.18371 and 633.23352, respectively. These results demonstrated that CPT-p-Leu can serve as a 
fluorescent probe for tracking LAP activity and monitoring CPT release.  
Enzyme Kinetic Parameters of CPT-p-Leu. To further investigate the capability of LAP to 
facilitate anti-cancer drug release from CPT-p-Leu, the gradual addition of LAP 0-0.1 U·mL-1 to a 
solution of CPT-p-Leu was monitored (Figure 1b). The fluorescence intensity of CPT-p-Leu increased 
steadily until it reached saturation at about 0.07 U·mL-1 LAP, suggesting that 0.07 U·mL-1 LAP can 
efficiently catalyze the hydrolysis of 10 µM CPT-p-Leu. Likewise, when different concentrations of 
CPT-p-Leu were systematically treated with 0.07 U·mL-1 LAP (Figure 1d), a dose-dependent 
fluorescence increase was observed, and 10 µM CPT-p-Leu was sufficient to saturate 0.07 U·mL-1 
LAP. These phenomena demonstrate that 0.07 U·mL-1 LAP and 10 µM CPT-p-Leu are the optimal 
amounts, to trigger anti-cancer drug release in cancer cells in a dose-dependent manner. Moreover, the 
kinetic values of CPT-p-Leu against LAP were also determined using the Michaelis-Menten 
equation,48 the Michaelis constant (Km) of the prodrug was estimated to be 54.02 µM, and the 
maximum velocity (Vmax) values was 13.38 µM·min-1, which indicates that CPT-p-Leu has an excellent 
affinity for LAP. 
 Figure 1. (a) Time-dependent fluorescence spectra of CPT-p-Leu (10 μΜ) upon treatment with LAP 
(0.07 U·mL-1). Inset: photo of CPT-p-Leu solution before and after treatment with LAP. (b) 
Fluorescence spectra of CPT-p-Leu (10 μΜ) incubated with various concentrations of LAP (0, 0.01, 
0.02, 0.03, 0.04, 0.05, 0.07, 0.1 U·mL-1, respectively) for 30 min. (c) Time-dependence fluorescence 
intensity at 432 nm for CPT-p-Leu (10 μΜ) treatment with (red) or without (black) of LAP (0.07 U·mL-
1). (d) The emission spectra of different concentration of CPT-p-Leu incubated with LAP (0.07 U·mL-
1) for 30 min. λex = 350 nm. 
 
pH Effect. The pH effect on the drug release of CPT-p-Leu was also evaluated. As illustrated in 
Figure S15, in the absence of LAP, the fluorescence intensity at 432 nm for CPT-p-Leu is stable over 
a pH range from 5 to 9. Whilst in the presence of LAP CPT-p-Leu has a good response to LAP over a 
pH range from 5 to 9. These observations indicate that our prodrug (CPT-p-Leu) is a potential 
theranostic agent suitable for delivering anticancer drugs to cancer tissues over a biological pH range. 
Selectivity of CPT-p-Leu. Subsequently, the performance of CPT-p-Leu with other biological 
relevant analytes was evaluated. To verify CPT-p-Leu possess a high specificity to LAP, the prodrug 
was incubated with various metal ions, biological reductants, and several kinds of enzymes. However, 
as can be seen from Figure 2, only LAP triggers a fluorescence increase and no significant fluorescence 
response was observed with other analytes. These results demonstrate that CPT-p-Leu can selectively 
react with LAP in a cellular environment. 
 
Figure 2. Fluorescence responses of CPT-p-Leu (10 μM) treatment with LAP and other analytes in 
aqueous solution (PBS, 10 mM, pH 7.4) for 30 min, λex = 350 nm. Labels: a: free; b: K+; c: Zn2+; d: 
Ca2+; e: HS-; f: GSH; g: Cys; h: glucoamylase; i: cellulase; j: lipase; k: α-amylase; l: aprotinin; m: 
sulfatase; n: Tyr; o: ELA; p: α-Chy; q: GGT; r: LAP. Error bars represent standard deviation of three 
independent experiments. 
 
Live Cell Imaging. Based on these observations where LAP can trigger anticancer drug release with 
concurrent fluorescence activation, CPT-p-Leu was evaluated in cells. HeLa cells were first utilized 
for evaluating the cellular uptake and fluorescence intensity changes. The fluorescence confocal 
imaging results are illustrated in Figure 3, free HeLa cells show negligible fluorescence in the blue 
channel. Whilst after 30 min incubation with CPT-p-Leu, a strong fluorescence signal was observed. 
Furthermore, in order to confirm the fluorescent signal was caused by LAP, inhibitor experiments were 
conducted. Firstly, HeLa cells were pretreated with inobestin (a LAP inhibitor) for 30 min, and then 
CPT-p-Leu was added, and the system was further incubated for another 30 min. As shown in Figure 
3h and j, the fluorescence intensity was significantly suppressed by inobestin.  
 
 
Figure 3. Confocal images of HeLa cells in the absence (a-c) or presence (d-f) of CPT-p-Leu (10 μΜ) 
for 30 min. For the inhibition experiment (g-i), HeLa cells were pretreated with inobestin (50 μΜ) for 
30 min and then CPT-p-Leu (10 μΜ) was added and further incubated for another 30 min. (a, d, g) 
DIC images, (b, e, h) FITC channels (425 nm- 470 nm), (c, f, i) overlapped images. (j) Average 
fluorescence intensity. Error bars represent standard deviation of three independent experiments. Scale 
bars = 20 μm. 
 
In addition, in order to confirm that CPT-p-Leu is selectively activated in LAP overexpressing cancer 
cells but not in normal cells, a series of control cell imaging assays were carried out using HEK 293 
cells as the control. As shown in Figure S16 and S17, a significantly brighter fluorescence was 
observed in A549 cells compared to the control cells, which suggests that CPT was released more in 
the cancer cells. Moreover, we monitored the process of drug release and drug distribution in A549 
cells with fluorescence microscopy. As shown in Figure 4, with increasing incubation time, CPT was 
gradually released to the cytoplasm, followed by entry into the nucleus, as determined by fluorescence 
co-localization with a nucleus tracker (Pi: Propidium iodide). These results demonstrated that the 
fluorescence enhancement was caused by LAP in cancer cells. At the same time, the anticancer drug, 
CPT, was released and the fluorescence signal distribution in these cells indicated the drug localization. 
 
 Figure 4. Confocal images of A549 cells. Cells were treated with 10 μΜ prodrug for (A-D) 10 min, 
(E-H) 30 min, and (I-L) 60 min, then the cells were co-stained with Nuclei-Tracker (Pi: red). (A, E, I) 
DIC images, (B, F, J) blue channel (425 nm- 470 nm), (C, G, K) red channel (590 nm- 650 nm), (D, 
H, L) merged images. (M) Average fluorescence intensity in blue channel. Error bars represent 
standard deviation of three independent experiments. Scale bars = 20 μm. 
 
Subsequently, cell viability experiments were carried out to assess CPT-p-Leu cytotoxicity towards 
LAP overexpressing cancer cells (A549) and normal cells (HEK 293) using typical MTT assays. As 
shown in Figure 5, CPT-p-Leu displays relatively strong cytotoxicity towards A549 cells, and the cell 
viability was under 40% when incubated with the prodrug at 20 µM for 24 h. However, cytotoxicity 
was significantly lower for the non-LAP overexpressing normal cell, HEK 293, and the cell viability 
was over 70% when treated under the same conditions. These results indicated that CPT-p-Leu can 
selectivity harm LAP overexpressing cancer cells.  
 Figure 5. Cell viability of HEK 293 and A549 cell lines incubated with CPT-p-Leu and CPT at various 
concentrations for 24 h. Error bars represent standard deviation of five independent experiments. 
 
CONCLUSION 
In this study, a new LAP-activatable theranostic prodrug, CPT-p-Leu, was developed. Upon 
interaction with LAP, the cleavage of the amide bond in CPT-p-Leu is facilitated followed by an 
intramolecular 1, 6-elimination, which triggers release of the active anticancer drug (CPT) and restores 
the fluorescence of CPT. Therefore, CPT-p-Leu can be used for the chemoselective detection of LAP 
and real-time monitoring of anticancer drug release. Furthermore, the anti-cancer drug CPT, serves as 
the reporter, and allows accurate determination of the location of the released drug in living samples. 
In addition, CPT-p-Leu shows good cell membrane permeability and enhanced cytotoxicity toward 
LAP overexpressing cancer cells. We anticipate that our strategy of using anti-cancer drugs, which 
serve as both a bioactive molecule and the signal reporter, make these systems suitable for the accurate 
and effective real-time tracking of released drugs. Which will help provide useful insight for the 
development of future theranostic systems for cancer diagnosis and treatment. In addition, we 
anticipate that our work will help provide guidance in the development of new and improved 
theranostic systems for cancer therapy. 
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